Last reviewed · How we verify
Ropivacaine 0.2% + Dexamethasone — Competitive Intelligence Brief
phase 3
Local anesthetic with corticosteroid adjuvant
Voltage-gated sodium channels (ropivacaine); glucocorticoid receptor (dexamethasone)
Anesthesia / Pain Management
Small molecule
Live · refreshed every 30 min
Target snapshot
Ropivacaine 0.2% + Dexamethasone (Ropivacaine 0.2% + Dexamethasone) — Instituto do Coracao. Ropivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and edema at the injection site.
Comparator set (5 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ropivacaine 0.2% + Dexamethasone TARGET | Ropivacaine 0.2% + Dexamethasone | Instituto do Coracao | phase 3 | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (ropivacaine); glucocorticoid receptor (dexamethasone) | |
| Bupivacaine 0.5% , Dexamethasone | Bupivacaine 0.5% , Dexamethasone | Sisli Hamidiye Etfal Training and Research Hospital | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Bupivacaine and Dexamethasone Injection | Bupivacaine and Dexamethasone Injection | Colette Curtis MD | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Bupivacaine Hydrochloride combined with dexamethasone | Bupivacaine Hydrochloride combined with dexamethasone | Zhejiang Cancer Hospital | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone) | |
| Ropivacaine + dexamethasone | Ropivacaine + dexamethasone | Sahiwal medical college sahiwal | marketed | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels; glucocorticoid receptor | |
| Ropivacaine and dexamethasone | Ropivacaine and dexamethasone | University of Texas Southwestern Medical Center | phase 3 | Local anesthetic with corticosteroid adjuvant | Voltage-gated sodium channels; glucocorticoid receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Local anesthetic with corticosteroid adjuvant class)
- Colette Curtis MD · 1 drug in this class
- Instituto do Coracao · 1 drug in this class
- Sahiwal medical college sahiwal · 1 drug in this class
- Sisli Hamidiye Etfal Training and Research Hospital · 1 drug in this class
- University of Texas Southwestern Medical Center · 1 drug in this class
- Zhejiang Cancer Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ropivacaine 0.2% + Dexamethasone CI watch — RSS
- Ropivacaine 0.2% + Dexamethasone CI watch — Atom
- Ropivacaine 0.2% + Dexamethasone CI watch — JSON
- Ropivacaine 0.2% + Dexamethasone alone — RSS
- Whole Local anesthetic with corticosteroid adjuvant class — RSS
Cite this brief
Drug Landscape (2026). Ropivacaine 0.2% + Dexamethasone — Competitive Intelligence Brief. https://druglandscape.com/ci/ropivacaine-0-2-dexamethasone. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab